Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
This study investigates the safety and efficacy of the combination therapy with BAY86-9766
and sorafenib in patients with liver cancer. Safety will be determined by laboratory and
other evaluations. Efficacy of the combination BAY86-9766 and sorafenib will be determined by
disease control rate, overall survival, time to progression, response rate and duration of
response.